Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXIT-SEP: Xuebijing Injection in Sepsis
NCT03238742Phase 4Completed
- Sponsor
- Southeast University
- Start
- Oct 2017
- Primary completion
- Jul 2019
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of xuebijing in sepsis (2 arms), sponsored by Southeast University. Primary endpoint: All-Cause Mortality at 28 days. Started Oct 2017; status: completed.
02
Drugs
xuebijing
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT03238742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238742.